Yujie Li

Dr. Yujie Li

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 November 2025 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
XLXiaolong Liu
Xiaolong Liu
ZZZiyun Zhuang
Ziyun Zhuang
JCJiaxi Cheng
Jiaxi Cheng
YLYujie Li
Yujie Li
DLDuguang Li
Duguang Li
HLHui Lin
Hui Lin
Background: Hepatocellular carcinoma (HCC) continues to be a major cause of cancer associated deaths worldwide, highlighting the need for new prognostic biomarkers and treatment strategies. Triaptosis, a recently characterized mode of regulated cell death, has shown potential as a therapeutic target in various malignancies, including HCC. Nevertheless, how long non-coding RNAs (lncRNAs) regulate triaptosis, as well as their function in HCC, is still not well understood. Methods: This study integrates bioinformatics and functional validation to delineate the interplay between lncRNAs and triaptosis in HCC progression. Results: Firstly, we confirm that pharmacologically inducing triaptosis, a process centrally mediated by ROS accumulation, with menadione sodium bisulfite (MSB) can inhibit HCC growth both in vitro and in vivo. Furthermore, single-cell RNA sequencing identifies a specific elevation of the triaptosis-related gene MTM1 in malignant hepatocytes. Through systematic bioinformatics analysis of TCGA data, we develop a 5-lncRNA prognostic signature (LINC01134, HPN-AS1, DDX11-AS1, AC009283.1, AC009005.1) with superior predictive power over conventional clinical parameters. Strikingly, functional studies reveal that LINC01134 acts as a crucial oncogenic driver and its depletion suppresses proliferation, migration, and invasion while sensitizing cells to triaptosis via MTM1-mediated PI(3)P catabolism. Conclusions: Collectively, our study confirms that triaptosis is a therapeutically targetable signaling in HCC and proposes LINC01134 as a biomarker and therapeutic target, offering new insights into lncRNA-mediated regulation of cell death for precision oncology.

19 October 2026 in Polymers
Verified
Journal Article
Open access
PDF file
XCXiang Chen
Xiang Chen
YLYujie Li
Yujie Li
JCJiayi Chen
Jiayi Chen
WLWei Liu
Wei Liu
SZShengsheng Zhao
Shengsheng Zhao
HLHui Lin
Hui Lin
Fluorescent polymer platforms reveal different aspects of tumour mechanobiology, but the strength of the evidence behind their optical readouts varies. This narrative review distinguishes calibrated physical measurements, mechanically active therapies assessed by independent assays, and biochemical or delivery readouts. We classify polymer roles as emission generation, mechanical coupling, chemical gating, and carriage or localisation. Among the selected studies, polymer-assisted molecular rotors measured local microviscosity in mouse CT26 tumours, while fluorescent polyacrylamide inclusions enabled intravital solid-stress inference from calibrated deformation. PEG–gold tethers measured receptor tension in cancer-cell culture. Mechanically responsive fluorophores in synthetic networks remain enabling technologies without tumour validation. Our quantitative comparison covers formulation properties, optical operating conditions, calibration, and demonstrated biological settings, labelling unreported values and inapplicable metrics separately. A cholesterol-modifying polyrotaxane illustrates therapy supported by independent cellular mechanics assays; its fluorescence tracks distribution. Protease, pH, oxygen, and transcript probes provide complementary microenvironment or treatment-response information without directly measuring tissue stiffness. The evidence reviewed here establishes neither a clinically validated polymer-fluorescence biomarker of tumour mechanics nor a universal cross-platform performance ranking. Progress requires a defined physical variable and compartment, maintained formulation integrity, and evidence that the measured change informs a functional treatment outcome.

2 November 2026 in Biomedicines
Verified
Journal Article
Open access
PDF file
XCXiang Chen
Xiang Chen
YLYujie Li
Yujie Li
XLXiaolong Liu
Xiaolong Liu
JCJiayi Chen
Jiayi Chen
WLWei Liu
Wei Liu
HLHui Lin
Hui Lin
Background/Objectives: We assessed whether an ANXA1–ANXA2 expression score stratifies survival in intrahepatic cholangiocarcinoma (iCCA). Methods: We assessed the discovery model’s internal performance and examined independent cohorts, single-cell expression and immunohistochemistry (IHC). Results: The discovery cohort included 244 patients and 99 deaths. Bootstrap-corrected 1- and 3-year areas under the curve (AUCs) were 0.712 and 0.629, respectively, for the three-candidate procedure; broader screening retained an additional gene. TCGA-CHOL was inconclusive (36 tumours, 18 deaths; hazard ratio per score standard deviation 1.00, 95% CI 0.57–1.77). Cohort-standardised microarray analysis of 81 iCCA patients with 40 deaths supported a continuous association (hazard ratio 1.85, 95% CI 1.30–2.63). Median-split survival separation was not significant. Single-cell analysis included 19,278 cells from ten libraries and nine patients, with immune cells present in the initial epithelial-enriched selection. Within-patient ANXA2–oxidative-phosphorylation associations were positive, but none of the 16 patient-pseudobulk tests passed false discovery rate (FDR) correction. IHC showed descriptive differences in three matched tumour–adjacent pairs per marker, using different patient sets and no inferential testing. Conclusions: The score remains exploratory. Interpretation depends on candidate selection, differences between assays and patient-level uncertainty. Clinical utility and causal mechanisms require further evaluation.